[{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Aliada Therapeutics","amount2":1.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"12","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Aliada Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : AbbVie will acquire Aliada and it's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease.

                          Brand Name : ALIA-1758

                          Molecule Type : Large molecule

                          Upfront Cash : $1,400.0 million

                          October 28, 2024

                          Lead Product(s) : ALIA-1758

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : AbbVie Inc

                          Deal Size : $1,400.0 million

                          Deal Type : Acquisition

                          blank